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Abstract
Background: Although trazodone is frequently used by fibromyalgia patients, its efficacy on this disease has not
been adequately studied. If effective, pregabalin, whose beneficial effects on pain and sleep quality in fibromyalgia
have been demonstrated, could complement the antidepressant and anxiolytic effects of trazodone. The aim of
the present study was to assess the effectiveness of trazodone alone and in combination with pregabalin in the
treatment of fibromyalgia.
Methods: This was an open-label uncontrolled study. Trazodone, flexibly dosed (50-300 mg/day), was administered
to 66 fibromyalgia patients during 12 weeks; 41 patients who completed the treatment accepted to receive
pregabalin, also flexibly dosed (75-450 mg/day), added to trazodone treatment for an additional 12-week period.
Outcome measures included the Fibromyalgia Impact Questionnaire (FIQ), the Pittsburgh Sleep Quality Index
(PSQI), the Beck Depression Inventory (BDI), the Hospital Anxiety and Depression Scale (HADS), the Brief Pain
Inventory (BPI), the Short-Form Health Survey (SF-36), and the Patients’ Global Improvement scale (PGI). Emergent
adverse reactions were recorded. Data were analyzed with repeated measures one-way ANOVA and paired
Student’s t test.
Results: Treatment with trazodone significantly improved global fibromyalgia severity, sleep quality, and
depression, as well as pain interference with daily activities although without showing a direct effect on bodily
pain. After pregabalin combination additional and significant improvements were seen on fibromyalgia severity,
depression and pain interference with daily activities, and a decrease in bodily pain was also apparent. During the
second phase of the study, only two patients dropped out due to side effects.
Conclusions: Trazodone significantly improved fibromyalgia severity and associated symptomatology. Its
combination with pregabalin potentiated this improvement and the tolerability of the drugs in association was
good.
Trial Registration: ClinicalTrials.gov: NCT00791739
Background
Disturbed sleep is a prominent feature of fibromyalgia
symptomatology and has been proposed as one of the
core symptoms that should be systematically assessed in
clinical trials for the treatment of fibromyalgia [1]. Tra-
zodone is an old second-generation antidepressant with
strong sedative activity, widely used as a hypnotic drug
in subtherapeutic antidepressant doses of 100 mg or
less, although the evidence of the efficacy of this drug in
treating insomnia in nondepressed patients is very lim-
ited [2]. Despite this relative paucity of data, low-dose
trazodone is frequently used in fibromyalgia manage-
ment to improve sleep quality [3]. In a recent Internet
survey of people with fibromyalgia, 33% of the patients
reported having used trazodone; within this group, the
36% of respondents reported continuing to use the drug,
with 51% finding it useful [4]. In fact, as symptoms of
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myalgia patients, the acknowledged antidepressant and
anxiolytic properties of trazodone [5] could be useful in
treating other symptoms of fibromyalgia in addition to
insomnia.
However, the efficacy of trazodone for fibromyalgia,
either as a hypnotic or as an antidepressant, has not
been adequately investigated. Only one study, which was
published in abstract form, evaluated the polysomno-
graphic and clinical effects of trazodone in women with
fibromyalgia [6]. The authors stated that two-month
treatment with trazodone increased slow-wave sleep and
reduced alpha activity but did not improve pain or psy-
chological distress. However, their study included only
13 patients and they did no mention the daily dosage of
trazodone that was used.
Although monotherapy would be the optimal treat-
ment approach in fibromyalgia, the multidimensional
nature of the disease and its high comorbidity with
other disorders often leads to the use of polypharmacy.
Patients with a wide range of symptoms frequently
r e q u i r et h es i m u l t a n e o u su s eo fm o r et h a no n ed r u g ,
and the need to prescribe two or more drugs for fibro-
myalgia management has been acknowledged [7,8]. In
fact, several observational, prospective and longitudinal
studies have found that the use of prescription drugs is
high among fibromyalgia patients [9], and that polyther-
apy is usual, with the mean number of drugs ranging
from 2.7 to 3.3 per patient [10-12]. Therefore, combina-
tion therapy, using drugs targeting different symptoms
of the disease, seems worthy of being explored.
Pregabalin was the first drug to be approved by the
FDA for the treatment of fibromyalgia and has been
shown to improve pain, sleep and quality of life but to
be ineffective against depression [13]. As such, its clini-
cal profile could be complementary of trazodone’s clini-
cal profile, which lacks analgesic activity but has an
antidepressant effect. On the other hand, the mechan-
isms of action of both drugs are quite different, with tra-
zodone exhibiting 5-HT2, a1, and H1 blocking properties
and inhibiting serotonin presynaptic uptake, and prega-
balin being a ligand on the a2δ subunit of type P/Q cal-
cium channels. Thus, the combination of both drugs
may be considered as a rational polytherapy both from a
pharmacodynamic and a clinical point of view.
Accordingly with the above-mentioned considerations,
we designed a two-phase study intended to assess the
effectiveness and tolerability of flexibly dosed trazodone
in the treatment of fibromyalgia and to evaluate whether
the addition of pregabalin to those patients who were
partially responsive to trazodone had additionally
improved fibromyalgia symptomatology. The results of
the first phase of the study showed that trazodone ther-
apy markedly improved sleep quality and also had a
positive and statistically significant effect on fibromyal-
gia severity, depression, anxiety and pain interference
with daily activities but it did not improve pain intensity
itself; the most frequent and severe side effect associated
with trazodone in our sample was tachycardia, which
was reported by 21% of the patients [14].
The main objective of the present study was to evalu-
ate whether pregabalin augmentation additionally
improved fibromyalgia symptomatology. A secondary
objective was to assess the efficacy and tolerability of
trazodone in the subset of patients who completed the
first phase of the study and accepted to combine prega-
balin with trazodone.
Methods
This was a two-phase study, which each phase 12 weeks
in duration. During the first 12 weeks patients were
treated with trazodone, and during the following 12
weeks pregabalin was added to trazodone treatment.
The study included patients diagnosed of fibromyalgia
according to the American College of Rheumatology cri-
teria [15] and who were willing to discontinue their cur-
rently prescribed treatment. They were referred to our
unit by their physicians (general practitioners, rheumatolo-
gists and physicians from pain-management clinics).
Patients who had been previously treated with either tra-
zodone or pregabalin but failed to improve or did not tol-
erate either of these drugs were excluded, as were
pregnant or lactating women. Every patient gave informed
consent to participate in the study, which was approved by
the Ethics Committee of the University of Granada. The
trial registration number was NCT-00791739.
Before beginning the study, the patients were required
to withdraw from their current pharmacological medica-
tions prescribed for fibromyalgia. Nonpharmacological
treatments, herbal remedies, drugs used on a p.r.n.
basis, or drugs prescribed for associated pathologies
were allowed; as rescue medication for pain paraceta-
mol, up to 4 g daily, was recommended as the drug of
choice but NSAIDs or tramadol were also permitted.
After a patient-tailored washout period, trazodone was
administered at a starting dose of 25 mg at bedtime and
increased by 25 to 50 mg/day increments at two-week
intervals if the patient reported little or no clinical
improvement. The dosage increase was maintained until
a relevant clinical benefit was reached or side effects
appeared, the maximum allowed dosage being 400 mg
daily. Pregabalin was administered at a starting dosage
of 75 mg daily and dosage was increased, in 25 to 75
mg/day increments, at the same time intervals and
under the same clinical criteria, with a maximum
allowed dosage of 450 mg daily. During the second
phase of the study, trazodone daily dosage remained
unchanged, although if side effects potentially linked
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observed, it could be reduced. Patients were seen at
baseline and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and
24 weeks for dose adjustments. Clinical investigators
were responsible for drug dispensation, dosage adjust-
ments and adverse reactions monitoring.
Efficacy outcome measures included the Spanish-vali-
dated versions of the following scales: the Fibromyalgia
Impact Questionnaire (FIQ) [16], the Pittsburgh Sleep
Quality Index (PSQI) [17], the Beck Depression Inventory
(BDI) [18], the Hospital Anxiety and Depression Scale
(HADS) [19], the Brief Pain Inventory (BPI) [20], the
Short-Form Health Survey (SF-36) [21], and a Patients’
Global Improvement scale (PGI). Scales were adminis-
tered at baseline and at weeks 6, 12, 18 and 24, with the
exception of the SF-36, which was administered only at
baseline and at weeks 12 and 24. Emergent side effects to
trazodone and to trazodone plus pregabalin combination
were recorded at each patient’s visit by means of an
open-ended question; patients were also instructed to
phone the attending physician if they believed they were
experiencing any drug-related side effect.
Because this phase of the study aimed to evaluate the
usefulness of the trazodone plus pregabalin combina-
tion, the intention-to-treat (ITT) sample included those
patients who had started pregabalin and had had at least
a post-baseline assessment. Analysis of the ITT sample
was performed with the last-observation-carried-forward
approach (LOCF). Data were analyzed with repeated
measures ANOVA. Effect sizes were calculated accord-
ing to Cohen’s formula and were considered small when
lower than 0.50, moderate when ranging from 0.50 to
0.79, and large when equal to or greater than 0.80. Sta-
tistical analyses were performed using GraphPad Prism
version 5.
Results
As it can be seen in Figure 1, 66 of the 72 screened
patients started trazodone, and 43 of them completed
the first 12 weeks of the study. Six patients were unable
to complete the washout period complaining of worsen-
ing of their symptomatology. Of those, 41 patients who
improved under trazodone accepted to receive pregaba-
lin as add-on treatment. The 39 patients who had at
least a post-baseline assessment after starting pregabalin
constituted the ITT sample. Their demographic and
clinical data are shown in Table 1. Twenty-nine patients
withdrew from the study: 23 during the trazodone phase
and 7 during the pregabalin phase; reasons for withdra-
wal are shown in Figure 1.
Trazodone daily doses ranged from 50 to 300 mg with
mean ± sd values of 199 ± 71 at week 12 and 194 ± 78
at week 24. Pregabalin daily doses ranged from 75 to
450 (324 ± 92) mg.
As shown in Table 2, FIQ total scores decreased stea-
dily throughout the study period, with large effect sizes
from weeks 12 to 24. Significant decreases were seen in
most of the FIQ subscales scores, with large effects sizes
in the work, pain, fatigue, morning tiredness and stiff-
ness subscales at study endpoint. The improvement
observed in the pain subscale of the FIQ under trazo-
done treatment was not seen in the mean severity scale
of the BPI; however, a marked improvement in the
mean interference of pain with daily activity of this test
was apparent at both weeks 6 and 12 of trazodone treat-
ment (Table 3).
A responder analysis of the BPI mean severity scores
was done according to the IMMPACT criteria, consider-
ing a decrease in pain scores of 10-20% as minimally
important, a decrease ≥30% as moderately important,
and a decrease ≥50% as substantial [22]. During the first
phase of the study 12 (30.8%) of the 39 patients from
the ITT sample had a minimally important decrease in
pain scores, 5 (12.8%) patients had a moderately impor-
tant decrease in pain scores, and no patient had a sub-
stantial decrease in pain scores. At the end of the study,
after pregabalin addition, 11 (28.2%) patients had a
minimally important decrease in pain scores, 11 (28.2%)
patients had a moderately important decrease in pain
scores, and 7 (17.9%) patients had a substantial decrease
in pain scores (Figure 2).
PSQI total scores decreased markedly from baseline to
week 12, and remained unchanged from week 12 to week
24 (Table 4). This pattern of reduction was apparent in
most of the PSQI subscales, with particularly large effect
sizes in sleep quality, sleep duration and sleep efficiency.
T h es l e e pd i s t u r b a n c ew a st h eo n l yP S Q Is u b s c a l et h a t
improved significantly after pregabalin addition, with
relevant reductions between weeks 12 to 24 (p < 0.05).
Both depression and anxiety scores decreased signifi-
cantly during the study period especially among patients
with clinically relevant depression and/or anxiety at
baseline (Table 3). Effect sizes were large in BDI scores
and moderate in HADS anxiety and depression scores
from weeks 12 to 24.
Despite the improvements observed in fibromyalgia
severity, sleep quality, depression and anxiety, the only
domain of the SF-36 that showed a striking amelioration
was bodily pain, although a significant amelioration,
albeit with small to moderate effect sizes, was also seen
in physical function, role physical, vitality and mental
health (Table 5).
No relationship was found between trazodone dosage
at week 12 and the degree of improvement either in the
FIQ, PSQI or BDI scores.
A ss h o w ni nF i g u r e3 ,m o r ep a t i e n t sr e p o r t e dt ob e
better under the trazodone plus pregabalin combination
than when receiving only trazodone.
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side effects during the study period, most of them being
mild and transient. Tachycardia, dry mouth, dizziness
and lightheadedness were those side effects more fre-
quently reported during the trazodone phase of the
study, whereas dizziness, lightheadedness, dry mouth
a n de d e m aw e r et h es i d ee f f e c t sm o r ef r e q u e n t l y
reported with the trazodone plus pregabalin combina-
tion (Figure 4). Fourteen patients withdrew the study
because of tolerability problems, 12 of them during the
trazodone phase of the study and 2 of them during the
trazodone plus pregabalin phase of the study; 10 cases
of withdrawals were due to multiple side effects. There
were no reported serious side effects.
Discussion
Our data show that trazodone, in the range of doses
administered during the study, not only improved sleep
quality, but improved also fibromyalgia symptomatology,
as shown by the decrease in the FIQ scores. Morning
tiredness was the only FIQ subscale that was signifi-
cantly improved with large effect sizes from the first
evaluation of the study, probably reflecting the sleep-
improving properties of trazodone. Depression and anxi-
ety scores were also significantly improved at week 12,
although large effect sizes were only seen in BDI scores.
Trazodone treatment did not improve pain severity, as
measured by the BPI, but it had a large impact on pain
interference with daily activities, a fact that could also
perhaps be attributed to the sleep-improvement
Figure 1 Patients flow diagram.
Table 1 Demographic and clinical data of patients at
baseline
(N = 41)
Sex (female/male) 39/2
Age (years) (22-63)
(range and mean ± s.d.) 48 ± 10
Illness duration from diagnosis (years) (1-19)
(range and mean ± s.d.) 46 ± 4.1
Most frequent comorbidities [N (%)]:
Temporomandibular dysfunction 30 (73)
Migraine 19 (46.3)
Irritable bowel syndrome 13 (32)
Chronic fatigue syndrome 7 (17.9)
Thyroid disease 7 (17.9)
Rheumathoid arthritis 9 (23.1)
Previous pharmacological treatments [N (%)]:
Paracetamol 22 (53.6)
NSAIDs 27 (65.8)
Tramadol 12 (29.3)
Benzodiazepines 25 (60.9)
Antidepressants 19 (46.3)
Anticonvulsants: 3 (7.3)
pregabalin/gabapentin 1 (2.4)
Non-pharmacological therapies [N (%)]
Tai Chi 2 (4.9)
Swimming pool 2 (4.9)
Ozone therapy 1 (2.4)
Yoga 1 (2.4)
Physiotherapy 1 (2.4
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found when analyzing the data of all patients treated
with trazodone, i.e., including those who did not enter
in second phase of the study [14].
After the addition of pregabalin to trazodone, FIQ
scores continued to decrease, with the most evident
improvements appearing in morning tiredness, and the
pain and anxiety subscales, reflecting the well-known
sleep-improving, analgesic and anxiolytic effects of preg-
abalin. Sleep quality was not additionally improved
beyond the amelioration observed during trazodone
treatment, except for the sleep disturbance item the
scores of which decreased significantly between weeks
12 and 24. The most relevant improvement seen after
pregabalin addition was in bodily pain: the BPI mean
pain severity score decreased significantly in relation to
baseline, with a large effect size, and pain interference
with daily activities additionally decreased beyond the
initial improvement seen with trazodone.
It seems worthy of mention that the improvement in
the bodily pain domain of the SF-36 was already signifi-
cant at week 12, under trazodone treatment. This data
possibly reflects the fact that, although trazodone did
not have a significant impact on pain intensity, it
allowed the patient to better tolerate bodily pain when
performing customary activities.
Table 2 FIQ total scores and VAS subscales throughout the study (mean ± sd) (ES: effect sizes)
baseline week 6 week 12 week 18 week 24 P
Total scores 78.6 ± 11.5 72.2 ± 14.4 68.6 ± 16.6*** 66.5 ± 18.1*** 65.2 ± 18.5*** <0.0001
ES 0.56 0.88 1.06 1.17
Work 8.19 ± 1.4 7.44 ± 1.9* 7.21 ± 2.1** 7.17 ± 2.1** 6.77 ± 2.4*** <0.0001
ES 0.54 0.71 0.73 1.02
Pain 8.46 ± 1.4 7.92 ± 1.3 7.51 ± 1.8** 7.33 ± 1.09** 7.05 ± 2.3*** <0.0001
ES 0.38 0.70 0.81 1.04
Fatigue 8.72 ± 1.2 8.02 ± 1.9 7.92 ± 1.6** 7.97 ± 1.7** 7.55 ± 2.3*** <0.0001
ES 0.58 0.67 0.62 1.00
Morning tiredness 8.85 ± 1.2 7.64 ± 2.4 7.63 ± 2.4** 7.51 ± 2.3** 7.17 ± 2.4*** <0.0001
ES 1.00 1.02 1.12 1.39
Stiffness 8.44 ± 1.7 7.55 ± 2.5** 7.26 ± 2.6** 7.15 ± 2.6** 7.06 ± 2.5*** = 0.0006
ES 0.52 0.72 0.81 0.83
Anxiety 8.31 ± 1.7 7.47 ± 2.7 6.99 ± 2.5** 7.03 ± 2.4** 6.96 ± 2.4** = 0.0006
ES 0.49 0.78 0.75 0.78
Depression 7.90 ± 2.8 6.88 ± 2.9 7.01 ± 3.1 6.97 ± 2.7 6.85 ± 3.0 = 0.0754
ES 0.36 0.32 0.33 0.38
*: p < 0.5, **: p < 0.01 and ***: p < 0.001 in relation to baseline (Tukey’s post-test). Bold: large effect sizes.
Table 3 BPI, BDI and HADS scores throughout the study (mean ± sd) (ES: effect sizes)
baseline week 6 week 12 week 18 week 24 P
BPI mean severity 7.26 ± 1.6 6.69 ± 1.6 6.81 ± 1.8 6.33 ± 2-0 5.97 ± 2.3** 0.0028
ES 0.36 0.28 0.58 0.81
BPI mean interference with daily activities 8.13 ± 1.6 6.90 ± 2.1** 6.60 ± 2.4*** 6.48 ± 2.4*** 5.93 ± 2.8*** <0.0001
ES 0.77 0.95 1.03 1.38
BDI 28.0 ± 11.0 24.9 ± 13.1 21.5 ± 10.4*** 19.1 ± 9.9*** 19.3 ± 12.1*** <0.0001
ES 0.28 0.59 0.81 0.79
BDI > 18 (N = 32) 31.2 ± 9.3 27.5 ± 12.7 23.2 ± 10.4*** 20.4 ± 10.1*** 20.8 ± 12.5*** <0.0001
ES 0.40 0.87 1.16 1.12
HADS-A 13.9 ± 3.9 13.2 ± 4.5 12.0 ± 4.5* 11.9 ± 4.4** 11.5 ± 5.0** = 0.0003
ES 0.17 0.48 0.52 0.61
HADS-A > 7 (N = 37) 14.4 ± 3.4 13.7 ± 4 12.5 ± 4.1* 12.4 ± 4.0* 12.0 ± 4.6** = 0.0008
ES 0.19 0.56 0.60 0.71
HADS-D 12.2 ± 4.6 11.5 ± 4.7 10.6 ± 4.7 10.4 ± 5.0* 10.2 ± 4.9* = 0.0061
ES 0.16 0.36 0.41 0.45
HADS-D > 7 (N = 34) 13.3 ± 3.7 12.4 ± 4.2 11.2 ± 4.5* 11.0 ± 4.7** 10.7 ± 4.7** = 0.0007
ES 0.25 0.58 0.63 0.71
*: p < 0.05, **: p < 0.01 and ***: p < 0.001 in relation to baseline (Tukey’s post-test). Bold: large effect sizes.
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ing moderate and/or substantial decrease in bodily pain
during trazodone treatment markedly increased during
the second phase of the study, suggesting an enhance-
ment in analgesia following pregabalin addition to the
former drug. This observation is in agreement with the
substantial improvement seen in the bodily pain compo-
nent of the SF-36, and it is also consistent with pregaba-
lin results in previous controlled trials [23,24].
The fact that 12 out of the total of 14 withdrawals due
to adverse reactions occurred during the trazodone
phase of the study could be indicative that the tolerabil-
ity of trazodone is lower than that of pregabalin; in fact,
t h ea p p e a r a n c eo ft a c h y c a r d i aw a sam a j o ri s s u ew i t h
trazodone, being reported by 14 (21%) patients and lead-
ing to withdrawal of 6 patients during the first phase of
the study [14]. However, another explanation is also
possible: it is well known that fibromyalgia patients are
highly sensitive to drug side effects, and it seems likely
that patients who withdrew due to tolerability problems
during the first phase of the trial were those patients
more prone to be intolerant of any drug.
Studies concerning drug combination in the treatment
of fibromyalgia are scarce, and most of them are old. A
double-blind, placebo-controlled study comparing ami-
triptyline, naproxen and a combination of both drugs
found that either amitriptyline or amitriptyline plus
naproxen were significantly better than placebo or than
naproxen alone; however, the limited sample size of the
study did not allow the authors to conclude that the
minor differences between amitriptyline and amitripty-
line plus naproxen were statistically significant [25]. A
randomized, open-label study comparing low-dose
cyclobenzaprine alone with cyclobenzaprine in combina-
tion with ibuprofen found that only morning stiffness
improved significantly in the combination group in rela-
tion to the monotherapy group [26]. Another controlled
study, on the contrary, found that cyclobenzaprine plus
fluoxetine performed significantly better than cycloben-
zaprine alone, despite the limited sample size evaluated
[27]. Again, a double-blind crossover trial found that
amitriptyline-fluoxetine combination improved pain
scores and total FIQ scores more than either drug alone
and more than placebo [28]. Our group added pregaba-
lin to fibromyalgia patients already improved by quetia-
pine and found that pain and tiredness after awakening
subscales of the FIQ, as well as the physical component
Figure 2 Responder analysis of pain improvement in BPI
severity scores.
Table 4 PSQI total and component scores throughout the study (mean ± sd) (ES: effect sizes)
baseline week 6 week 12 week 18 week 24 P
Total scores 16.0 ± 3.2 12.4 ± 4.0*** 11.0 ± 4.6*** 11.2 ± 4.4*** 11.1 ± 5.1*** <0.0001
ES 1.19 1.56 1.50 1.53
Sleep quality 2.54 ± 0.5 1.67 ± 0.8*** 1.46 ± 0.8*** 1.44 ± 0.8*** 1.53 ± 0.9*** <0.0001
ES 1.74 2.16 2.20 2.02
Sleep latency 2.51 ± 0.7 2.10 ± 0.9 1.80 ± 1.1*** 2.08 ± 1.0* 1.87 ± 1.0*** <0.0001
ES 0.59 0.99 0.61 0.89
Sleep duration 2.56 ± 0.6 1.90 ± 1.0*** 1.56 ± 1.1*** 1.51 ± 1.2*** 1.54 ± 1.2*** <0.0001
ES 1.10 1.66 1.75 1.72
Sleep efficiency 2.62 ± 0.7 1.92 ± 1.2*** 1.72 ± 1.3*** 1.69 ± 1.2*** 1.62 ± 1.2*** <0.0001
ES 1.00 1.27 1.33 1.41
Sleep disturbance 2.33 ± 0.5 1.97 ± 0.6 1.85 ± 0.6** 1.97 ± 0.7 1.44 ± 1.0*** <0.0001
ES 0.72 0.90 0.72 1.68
Sleep medications 1.41 ± 1.4 0.82 ± 1.3 0.51 ± 1.1** 0.62 ± 1.2* 0.72 ± 1.2* = 0.0028
ES 0.42 0.62 0.56 0.48
Daytime dysfunction 2.28 ± 0.6 2.00 ± 0.9 1.95 ± 0.9 1.92 ± 0.9 1.92 ± 1.0 = 0.0454
ES 0.47 0.51 0.55 0.55
*: p < 0.05, **: p < 0.01, and ***: p < 0.001 in relation to baseline (Tukey’s post-test). Bold: large effect sizes.
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pregabalin combination [29]; the results of this study
were similar to those obtained with the combination of
pregabalin and trazodone in the present study. Recently,
an experimental study has shown, in an animal model
of fibromyalgia, a potent antihyperalgesic effect of tra-
madol combined with milnacipran [30].
The above-mentioned data, with the exception of the
two trials that evaluated a combination including an
NSAID, and the results of which are consistent with the
well-known fact that NSAIDs are not effective in the
long-term management of fibromyalgia, suggest that the
combination of two drugs with different mechanisms of
action contributed to improving patients’ outcomes.
Hence, it is important to perform additional combina-
tion trials with drugs potentially synergistic and/or tar-
geting different symptom domains.
Our results suggest that pregabalin treatment addi-
tionally improved the amelioration of fibromyalgia
symptomatology induced by trazodone, especially in
relation to physical pain. However, due to the uncon-
trolled design of our study, it is not possible to ascertain
whether this improvement was due solely to the combi-
nation of both drugs or if the longer period of treatment
also had a significant influence on the outcome.
As stated above, the main limitation of our study was
t h el a c ko fac o n t r o lg r o u pw h i c hw a sd u et ot h ef a c t
that no financial support was found to perform a clinical
trial. Trazodone is a relatively old drug without eco-
nomic interest for the pharmaceutical industry, which,
in addition, it is not usually interested in sponsoring
combination drug trials. For this reason, the study was
conceived as a preliminary research aiming to evaluate
the potential usefulness of an old drug, widely used but
scarcely investigated, in the management of fibromyal-
gia, as well as to assess whether its combination with
pregabalin, which has been demonstrated to relieve pain
in fibromyalgia patients, had an additive or synergistic
effect on fibromyalgia severity. This design of the trial
did not allow for controlling for a potential placebo
effect; thus, the effectiveness of the treatment could
have been overestimated, as it has been frequently
Table 5 SF-36 component scores throughout the study
(mean ± sd) (ES: effect sizes)
baseline week 12 week 24 P
PF (physical
function)
27.2 ±
18.4
29.2 ± 16.5 36.0 ± 21.4** =
0.0079
ES -0.11 -0.48
RP (role physical) 2.56 ±
12.6
8.33 ± 25.2 11.54 ± 28.0* =
0.0657
ES -0.46 -0.71
BP (bodily pain) 10.9 ±
14.4
18.2 ±
17.9*
24.2 ±
20.6***
<0.0001
ES -0.51 -0.92
GH (global health) 26.3 ±
17.9
28.4 ± 18.5 29.6 ± 17.4 =
0.4321
ES -0.12 -0.18
VT (vitality) 13.6 ±
13.4
18.7 ± 19.4 19.9 ± 18.6* =
0.0301
ES -0.38 -0.47
SF (social function) 35.6 ±
27.4
41.0 ± 28.5 42.2 ± 29.9 =
0.2150
ES -0.20 -0.26
RE (role emotional) 19.7 ±
32.2
24.8 ± 38.8 29.1 ± 39.9 =
0.3293
ES -0.16 -0.29
MH (mental health) 31.5 ±
21.5
38.1 ± 21.3 42.8 ± 24.6** =
0.0023
ES -0.31 -0.53
*: p < 0.05, **: p < 0.01 and ***: p < 0.001 in relation to baseline (Dunnett’s
post-test). Bold: large effect sizes.
Figure 3 Patients’ Global Improvement scale at weeks 12 and 24.
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Page 7 of 9observed when comparing non-controlled and con-
trolled trials [31].
Another relevant limitation of our study was the
restricted sample size. The recruitment period ranged
from September 2006 to July 2007 and our objective
was to include a greater number of subjects. However,
many of the contacted patients were not willing to give
up their previously prescribed medications and could
not be included in the trial.
Thirty-two (48%) of the 66 patients who started trazo-
done treatment did not complete the evaluation period.
Twenty-three of these patients withdrew during the first
phase of the study, 12 (52%) due to treatment-emergent
side effects; the remaining 11 withdrawals were losses of
follow up that could also have been due to trazodone
intolerance. Twelve (52%) of these 23 cases withdrew
during the first four weeks of the therapy [14]. This
high rate of early dropouts seems indicative of early
intolerance to the drug, suggesting that treatment with
trazodone should be closely monitored during the first
weeks of administration.
A longer evaluation period with each drug would have
allowed us to assess more thoroughly the effectiveness of
both trazodone and of its combination with pregabalin.
Nevertheless, this extension also would probably have
facilitated the withdrawal of those patients who experi-
enced only a marginal benefit with trazodone alone.
Our results could have been more striking if we had
excluded patients with associated diseases. However,
c o m o r b i d i t yi nf i b r o m y a l g i ai sm o r et h er u l et h a nt h e
exception [4,8] and, in doing so, the data obtained
would have been applicable to only to a very selective
type of patients.
Conclusion
Despite the limitations, we think that our data are indi-
cative that the beneficial effects of trazodone on fibro-
myalgia clearly exceed its hypnotic activity and that the
combination of trazodone with pregabalin can addition-
ally improve patients’ outcomes without increasing tol-
erability problems. Thus, we think that it will be worthy
to evaluate, in controlled studies, whether the combina-
tion of pregabalin with trazodone, or another sleep-
improving drug such as quetiapine or amitriptyline, is
associated with a better long-term treatment outcome
than either drug alone.
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